ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $32.06 million versus the consensus estimate of $31.88 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.